摘要
近视眼性脉络膜新生血管(mCNV)是病理性近视眼的严重并发症之一。目前的主要治疗方式为抗血管内皮生长因子(VEGF),虽可显著提高mCNV患者的视力,但存在复发率高,疗效不统一的问题。以往的研究认为,脉络膜变薄和缺血是导致脉络膜新生血管的重要原因,新近研究提示,除了脉络膜因素外,巩膜穿通血管(PSV)与mCNV发生、疗效等紧密联系。本文对PSV的定义,影像学分类及特征,PSV与mCNV的发生、临床疗效等进行全方位阐述,以期深入认识其在mCNV中的作用及潜在机制。
Myopic choroidal neovascularization(mCNV)is a severe complication of pathological myopia.Currently,the primary treatment involves anti-vascular endothelial growth factor(VEGF)therapy,which significantly improves visual acuity in mCNV patients.However,challenges such as high recurrence rates and inconsistent therapeutic outcomes persist.Previous studies attributed mCNV to choroidal thinning and ischemia.Recent research suggests that,in addition to choroidal factors,perforating scleral vessels(PSV)are closely associated with the occurrence and therapeutic efficacy of mCNV.This review comprehensively explores the definition of PSVs,their imaging classifications and features,as well as their intricate connections with the occurrence and clinical outcomes of mCNV.By delving into the role and potential mechanisms of PSVs in mCNV,this review aims to deepen our understanding of their involvement in this condition.
作者
姚王静
佘相均
沈丽君
Yao Wangjing;She Xiangjun;Shen Lijun(Eye Hospital of Wenzhou Medical University,National Clinical Research Center for Ocular Diseases,Wenzhou 325027,China;Department of Ophthalmology,Zhejiang Provincial People′s Hospital,People′s Hospital of Hangzhou Medical College,Hangzhou 310000,China)
出处
《中华眼科杂志》
CAS
CSCD
北大核心
2024年第1期90-94,共5页
Chinese Journal of Ophthalmology
基金
国家自然科学基金(82101158)
浙江省自然科学基金(LQ20H120004)。
